The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the safety of paclitaxel-coated devices used to treat peripheral artery disease (PAD) following its...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). This includes both metallic and bioresorbable drug-eluting stents and related clinical trial data.
-
-
February 22, 2019 — The U.S. Food and Drug Administration (FDA) has approved the Biotronik Orsiro drug-eluting stent (DES) system.
-
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
-
There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years ago.
News | Stents Drug Eluting | September 05, 2019
September 5, 2019 — Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target...
Feature | Peripheral Artery Disease (PAD) | August 28, 2019 | Jeff Zagoudis, Associate Editor
August 28, 2019 — The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the...
News | Stents | August 21, 2019
August 21, 2019 — Increasing incidence of cardiovascular diseases worldwide is creating growth opportunities for the...
Technology | April 03, 2019
April 3, 2019 — Medtronic's Resolute Integrity Zotarolimus-eluting Coronary Stent System received an additional U.S...
A comparison of stent strut thickness between the Orsiro stent, pictured, and the market-leading stents on the U.S. and European markets. Vendors have been working toward reducing strut thickness to help improve overall clinical outcomes. Orsiro is now the smallest strut stent available on the market.
Feature | Stents | February 22, 2019 | Dave Fornell, Editor
February 22, 2019 — The U.S. Food and Drug Administration (FDA) has approved the Biotronik Orsiro drug-eluting stent...
Two device technologies raised concerns in the industry based on recently released clinical data. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in a study questioning long-term safety of paclitaxel. The Abiomed Impella RP had higher than expected mortality in its post-approval study, possibly due to poor patient selection and implanting the device too late to aid the patient.
Blog | Cath Lab | February 20, 2019
Clinical study data makes the world go around in cardiology and is the basis of setting guidelines in evidence-based...
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.
Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The Medtronic Resolute Integrity drug-eluting stent (DES) is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data.
Feature | Stents | January 29, 2019 | Dave Fornell, Editor
There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.
Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since...
The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.
News | Stents | January 22, 2019
The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few...
News | Peripheral Artery Disease (PAD) | January 17, 2019
January 17, 2019 — The U.S. Food and Drug Administration (FDA) issued a letter...
Bioresorbable stents (BRS) in development, presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward.
Feature | Stents Bioresorbable | October 12, 2018 | Dave Fornell, Editor
Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology...
Videos | October 11, 2018
A discussion with Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president,...
The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.
News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials...
